Pricing Log in Create free account
Saturday 7 November 2026 Export LITS’s income statement to Excel — free account

Lite Strategy, Inc.

LITS Healthcare Biotechnology

Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023.

EPS
+5.80%
Free cash flow
+179.3%

Quarter to June 2026, against a year earlier

1.01 0.04 +4.12%
Market cap
$29.6M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−8.07
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.12
Sold, $m 0.95
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — — 1 — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 13.42%

Capital & Financial Ratios $m

Size
Market Cap 29.56
Revenue ttm 105.38
Net income ttm (71.15)
Free cash flow ttm (104.08)
Net debt Q (5.71)
Valuation
P/E 0.00
Forward P/E (0.46) (negative: loss-making)
Price / sales 0.33
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.84
Financial health
Current ratio Q 5.74 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q +647.96% (above 0%: growing)
Operating income growth Q −294.75% (below 0%: shrinking)
EPS, this year −335.21% (below 0%: weak)
EPS, next year A +34.80% (at or above 15%: strong)
Revenue, next year A −90.43% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −0.10% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.3×, against a ten-year median of 0.5×; over the ten years it ranged from −2.9× in 2022 to 79.9× in 2018.
P/S against its own 10 years 19.55%
10-year low 10-year high
P/B against its own 10 years 27.02%
10-year low 10-year high
EV/Sales against its own 10 years 11.24%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 101 38 18 6
Receivables 0 — — —
Inventory — — — —
Other — — — —
108 41 18 6
2023 2024 2025 2026
Payables 6 3 0 0
ST’ Debt — — — —
Other — — — —
20 8 1 1

Compound Annual Growth %

10y 5y 3y
Sales — 67.75% 23.34%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.01%) (3.39%) 19.12%

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 (0.12) (0.82) (0.66) (0.38) (2.06)
’25 (1.20) (0.40) (0.39) (0.40) (2.39)
’24 8.46 (1.66) (1.37) (2.76) 2.67
’23 (2.40) 1.60 (2.32) (1.51) (4.78)
’22 (3.07) (1.80) (1.40) (2.40) (10.00)
’21 0.12 (1.40) (5.60) (1.39) (7.22)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’24 65 — — — 65
’23 9 33 6 1 49
’22 8 12 10 11 41
’21 7 13 8 7 35
’20 1 1 1 24 28
’19 0 2 1 1 5
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (5) (2) (2) (1) (9)
’25 (11) (4) (3) (2) (21)
’24 (18) (11) (3) (18) (50)
’23 (15) (14) (12) (11) (52)
’22 (8) (9) (17) (16) (49)
’21 (9) 4 (16) (11) (32)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (105) (2) 0 2 (104)
’25 (11) (4) (3) (2) (21)
’24 (18) (11) (3) (18) (50)
’23 (15) (14) (12) (11) (53)
’22 (8) (9) (17) (16) (49)
’21 (10) 4 (16) (11) (33)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 23 2 5 28 35 41 49 65 — — +15.9% 25 — — —
Gross margin, % 78.49 (108.57) 13.27 90.38 95.95 100.00 100.00 100.00 — — +21.5 pt
EBT 3 (40) (17) (47) (41) (54) (32) 18 (16) (71) n/m
EBT margin, % 11.49 (2,470.22) (342.18) (169.95) (118.71) (133.80) (65.22) 27.23 0.00 0.00 (11.5) pt
Net income 3 (40) (17) (47) (41) (54) (32) 18 (16) (71) n/m
Per share, $
Per share, $ Revenue 12.63 0.78 1.38 6.09 6.18 6.54 7.33 9.80 0.00 0.00 n/m
Earnings 1.40 (19.40) (4.80) (10.20) (7.34) (8.80) (4.78) 2.67 (2.39) (2.06) n/m
Cash flow 1.89 (10.15) (8.27) 7.52 (5.68) (7.83) (7.88) (7.58) (3.13) (0.26) n/m
Capex (0.03) 0.00 (0.06) (0.20) (0.13) (0.08) (0.01) 0.00 0.00 (2.75) +66.7%
Free cash flow 1.87 (10.15) (8.33) 7.33 (5.81) (7.91) (7.88) (7.58) (3.13) (3.01) n/m
Book value 27.62 24.36 13.47 16.92 8.79 8.42 3.70 4.96 2.54 1.20 (29.4%)
Shares, m 2 2 4 5 6 6 7 7 7 35 +38.5%
Valuation, ×
Valuation, × P/E 39.83 0.00 0.00 0.00 0.00 0.00 0.00 1.07 — — 5.1
P/S 3.78 102.43 36.47 13.55 9.22 1.85 0.90 0.18 — — 21.0
P/B 1.73 3.29 3.74 4.88 6.48 1.44 1.78 0.58 — — 3.0
EV/Sales 1.48 39.09 21.32 6.97 4.81 (1.92) (1.16) (0.18) — — 8.8
EV/FCF 10.02 (3.01) (3.53) 5.80 (5.12) 1.58 1.08 0.38 — — 0.9
Cash, $m
Cash, $m Operating cash flow 3 (21) (29) 34 (32) (49) (52) (50) (21) (9) n/m
Capex 0 — 0 (1) (1) 0 0 0 0 (95) +130.9%
Free cash flow 3 (21) (30) 33 (33) (49) (53) (50) (21) (104) n/m
Balance, $m
Balance, $m Working capital 50 96 68 195 145 143 87 32 17 5 (22.5%)
Net debt (54) (103) (74) (183) (153) (153) (101) (38) (18) (6) (22.0%)
Shareholders’ equity 51 50 48 77 49 52 25 33 17 42 (2.2%)
Returns, %
Returns, % ROA 5.19 (49.97) (17.96) (32.27) (21.53) (30.95) (21.32) 21.92 (53.45) (233.37) (238.6) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (115.85) (115.9) pt
ROE 5.77 (79.11) (34.19) (75.48) (65.30) (106.90) (82.66) 61.68 (63.84) (243.02) (248.8) pt
People
People Employees 25 32 40 51 76 102 46 28 4 5 (16.4%)
Revenue/emp, $m 0.93 0.05 0.12 0.54 0.46 0.40 1.06 2.33 0.00 0.00 n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2024 · latest quarter Sep 2023 · fundamentals updated 2 Nov 2026

Lite Strategy, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EYPT EyePoint, Inc. $30.7M — (loss-making) — (loss-making) −90.49% (below 0%: shrinking) n/m +0.41% (above 0%: growing) 100.00% (19,207.10%) Compare
IRLA IRulya Therapeutics Inc. $29.8M — (loss-making) — — n/m −63.65% (below 0%: shrinking) 0.00% 0.00% Compare
LITS Lite Strategy, Inc. $29.6M — (loss-making) — (loss-making) +647.96% (above 0%: growing) n/m +179.28% (above 0%: growing) 0.00% 0.00%
EDSA Edesa Biotech, Inc. $28.8M — (loss-making) — (loss-making) −99.88% (below 0%: shrinking) n/m −81.24% (below 0%: shrinking) 0.00% 0.00% Compare
ANVS Annovis Bio, Inc. $28.6M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
BCTX BRIACELL THERAP $28.6M — (loss-making) — — n/m +26.73% (above 0%: growing) 0.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $28.2M — (loss-making) — (loss-making) +287.18% (above 0%: growing) n/m +105.91% (above 0%: growing) 100.00% (762.98%) Compare
MGX Metagenomi Therapeutics, Inc. $27.6M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
PLRZ Polyrizon Ltd. $27.5M — — — — −744.51% (below 0%: shrinking) — — Compare
Median of peers $28.6M — — −95.19% — −31.62% 50.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 December 2025

Ownership

Directors and executive officers, together 1.60%
Alexander Schornstein 11.87%
Citadel CEMF Investments Ltd 9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Lite Strategy, Inc. (LITS) Latest News

17 Oct

Impact 3 · · 24/7 Wall St.

12 Aug

Impact 4 · · Stocktwits
Impact 4 · · Business Wire

23 Jun

Impact 3 · · ccn.com

18 Jun

Impact 4 ·

25 Apr

Impact 3 ·

28 Aug

Impact 3 · · cryptonews.com

5 Aug

Impact 3 · · Benzinga
Impact 3 · · decrypt.co

21 Jul

Impact 4 · · The Motley Fool

20 Jul

Impact 4 ·

18 Jul

Impact 4 · · etf.com
Impact 4 · · Bloomberg

13 May

Impact 3 · · Business Wire

12 Feb

Impact 3 ·

12 Nov

Impact 4 · · Business Wire

19 Sep

Impact 4 · · Business Wire

22 Jul

Impact 4 · · Business Wire

1 Jul

Impact 4 · · InvestorPlace

9 May

Impact 4 · · Business Wire

11 Apr

Impact 4 · · Business Wire
Impact 4 · · Business Wire

10 Apr

Impact 3 · · Business Wire

26 Mar

Impact 4 · · Business Wire

9 Mar

Impact 4 · · Insider Monkey

13 Feb

Impact 4 · · Business Wire
Impact 3 · · Zacks

8 Feb

Impact 4 · · Insider Monkey

16 Jan

Impact 4 · · Business Wire

11 Dec

Impact 4 ·
stockrow.com/LITS · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com